Open AccessEffects of Atazanavir/Ritonavir or Fosamprenavir/Ritonavir on the Pharmacokinetics of Rosuvastatin
Author(s) -
Anthony J. Busti,
Amy M. Bain,
Ronald G. Hall,
Roger Bedimo,
Richard D. Leff,
Claudia Meek,
Reza Mehvar
Publication year - 2008
Publication title -
journal of cardiovascular pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.762
H-Index - 100
eISSN - 1533-4023
pISSN - 0160-2446
DOI - 10.1097/fjc.0b013e31817b5b5a
Subject(s) - ritonavir , rosuvastatin , pharmacokinetics , cmax , lopinavir , atazanavir , pharmacology , rosuvastatin calcium , bioavailability , medicine , lopinavir/ritonavir , viral load , virology , human immunodeficiency virus (hiv) , antiretroviral therapy
Rosuvastatin (RSV) is a potent statin with a lower potential for drug interactions. However, recent data have revealed unexpected increases in RSV concentrations with lopinavir/ritonavir. The objective is to study the pharmacokinetic interaction of RSV with atazanavir/ritonavir (ATV/RTV) or fosamprenavir/ritonavir (FPV/RTV).